# A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

> **NCT07160634** · PHASE3 · RECRUITING · sponsor: **Solid Biosciences Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** SGT-003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07160634
- **Lead sponsor:** Solid Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2029-01
- **Final completion:** 2034-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07160634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07160634, "A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07160634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*